Targeting IL-23 for Therapeutic Longevity in Psoriasis

Slides:



Advertisements
Similar presentations
Secukinumab Retreatment Shows Rapid Recapture of Treatment Response: An Analysis of a Phase 3 Extension Trial in Psoriasis
Advertisements

Difficult-to-Treat Psoriasis: Gaining Control of Palmoplantar and Nail Psoriasis.
The Nurse View: Management of Pancreatic Cancer
Psoriasis What’s New Dr. Vincent P Beltrani
Psoriatic Arthritis.
Evolution of Treatment Strategies Targeting IL-23 for Psoriasis
IL-12 and IL-23.
Effective Management of Psoriatic Arthritis: Tailoring Treatments
Clinical Developments in Inflammatory Arthritis 2017
Goals of Therapy for Patients With UC
Optimizing Use of Biological Agents in Ulcerative Colitis
Introduction/Background
Introducing JAK Inhibitors in Rheumatoid Arthritis
Changing the IBD Paradigm
Perspectives in Psoriasis: Assessing Treatment Efficacy—Which Measures, What Do They Tell Us?
From Conference to Practice: Big Data in Psoriasis
Biological Therapy in Psoriasis: Recognizing the Value
Managing Hereditary Angioedema
Expert Insights on Psoriatic Arthritis From Washington, DC
Neoadjuvant Therapy in HER2-Positive Breast Cancer
Comparing Treatment Alternatives in Ankylosing Spondylitis
Optimizing Patient Outcomes in IBD
IL-17 Inhibitors in the Management of Psoriatic Disease
What Is a Biosimilar?. Biosimilar Application in RA Clinical Practice: Current Knowledge and New Data  
Program Introduction. Monoclonal Antibodies and Immunogenicity: Relevance to Clinical Practice?
Clinical Updates in RA: New Developments and Insights From Washington
Patient Case: KC. Optimizing Treatment of Mild to Moderate Ulcerative Colitis: A Case-Based Perspective.
Next-Gen Psoriasis Therapies:
Managing IBD.
Atopic Dermatitis. Introduction to a Clinical Course On New Developments In Atopic Dermatitis.
WORCESTERSHIRE PATHWAY for use of CYTOKINE MODULATORS in
Understanding Comparative Effectiveness Data in Psoriatic Arthritis
Program Goals Overview Glatiramer Acetate 3 Times a Week.
Evolving Treatment Landscape for PsA
Advancing the Treatment of IBD With Biologics
New Data on Emerging Treatments for Psoriasis
When Is Biologic Therapy Appropriate for HS?
Improving Outcomes in Psoriatic Arthritis
The Evolving Treatment Landscape in Atopic Dermatitis
Best Clinical Pearls in Hidradenitis Suppurativa:
What's New in Therapeutic Options for Moderate to Severe RA?
Advancing Patient Care in RA
The Multifaceted Nature of Psoriasis Addressing Patients' Needs
CAD and HF Often Coexist
Safety, efficacy, and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis Alexander Egeberg, MD PhD; Mathias Bo Ottosen,
Ask the Psoriasis Expert
Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.
Patient Questions and Expert Answers in Psoriasis:
Application of Biologics in IBD:
Update on the Management of Atopic Dermatitis
EXPERT INSIGHTS: IL-17 INHIBITION IN PSORIASIS CARE
What Does the Future Hold and What Will It Mean for Patients?
Essential Updates for PsA: A Complex Disease to Manage
Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.
Pathogenesis of IBD, and the Role of Biologic Therapies
PAH Pathways: What Do the Data Tell Us?”
Understanding How IL-23p19 Inhibitors Work in Psoriasis
Enthesitis in Psoriatic Arthritis: Disease, Diagnosis and Decisions
A. Al-Janabi1, Z. K. Jabbar-Lopez2, C.E.M. Griffiths1, Z.Z.N. Yiu1
Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: A pooled analysis of the Phase 3 VOYAGE 1 and VOYAGE.
Treatment Advances for RA
Program. The Impact of Treatment Success and Failure in Psoriasis: Implications for Clinical Practice.
Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure
Biosimilars in Immune-Related Diseases
Areas of Special Interest in PsO
Patient Heterogeneity in CD
Meet the JAKs.
Psoriatic Arthritis.
You Don't Know JAK in IBD.
Women With Psoriasis Are Struggling More Than Men
Presentation transcript:

Targeting IL-23 for Therapeutic Longevity in Psoriasis

Activity Components

An Introduction to the Immunopathogenesis of Psoriasis and Rationale for Targeted Biologics: Why Target IL-23?

Key Cytokines Involved in Psoriasis Pathogenesis

Consequences of IL-23 Specific Inhibition

IL-23 as a Master Switch in Psoriasis

Summary

IL-23 Inhibitors for Biologic-Naive Psoriasis Patients

IL-23 Inhibitors in Moderate to Severe Psoriasis -- Approved and in Latest Development Stages

Guselkumab vs Adalimumab: VOYAGE-1 and VOYAGE-2

Guselkumab vs Secukinumab: ECLIPSE

Tildrakizumab vs Etanercept: reSURFACE-1 and reSURFACE-2

Risankizumab vs Ustekinumab -- ultIMMA and Risankizumab vs Adalimumab -- IMMvent

Mirikizumab: PASI 90 at Week 16 Phase 2 Study

Ranking of IL-23p19 Inhibitors -- Expert Perspective

IL-23p19 Inhibitors -- Insights on Remission and Disease-Modifying Effect

Summary

IL-23 Inhibitors for Biologic-Experienced Psoriasis Patients

Advantages of IL-23p19 Inhibitors

IL-23 Inhibitors in PsA

Advantages of IL-23p19 Inhibitors (cont)

Safety: IL-17 and IL-23p19 Inhibitors

Summary

IL-23 Inhibitors: Where They Fit in the Treatment Paradigm and Their Impact on Clinical Practice

Patient-Based Approach to Care

Secukinumab After Anti-TNF-α Failure

Long-Term Responses From Guselkumab vs Secukinumab in the ECLIPSE Trial

Patient-Specific Factors When Choosing IL-23 Antagonist Therapy

Summary

Abbreviations